Patrick j . McEnany
联合创始人、董事长、总裁兼首席执行官

Patrick J. McEnany，他一直担任Catalyst的首席执行官和董事(2002年1月公司成立以来)。2006年，他成为董事长、总裁和首席执行官。从1991年到1997年4月，他担任Royce Laboratories, Inc.的董事长兼首席执行官。从1997年到1998年，在Royce并入Watson Pharmaceuticals, Inc.之后，他担任全资拥有的Royce Laboratories子公司的总裁和Watson Pharmaceuticals, Inc.的企业发展副总裁。从1993年到1997年，他还担任National Association of Pharmaceutical Manufacturers的副主席和董事。他目前任职于杰克逊纪念医院基金会的董事会。

Philip H. Coelho

Philip H. Coelho, Thermogenesis Corp.的创始人兼首席技术官(CTO)，是一名工程师和发明家，在加州大学戴维斯分校(University of California, Davis)接受教育，专攻热力学和机械设计。他拥有40多项美国专利，涉及细胞选择、细胞低温保存、细胞洗涤、细胞自动低温冷冻和存储以及从血液中获得凝血蛋白。作为Thermogenesis Corp.的创始人、董事长和首席执行官，Coelho先生开发了Thermoline超快速血浆冷冻和解冻;用于从手术患者血液中制备纤维蛋白密封胶的CryoSeal自动化系统;BioArchive机器人系统用于控制速率冷冻和低温保存来自胎盘/脐带血的造血干细胞和祖细胞(hspc);以及自动压印系统，它可以自动将脐带血中的热休克蛋白采集到一个25毫升的双室冷冻袋中。BioArchive和AutoXpress系统在脐带血加工和储存方面建立了全球最高质量的GMP标准。Coelho先生于2007年8月从Thermogenesis Corp退休。2009年，Coelho先生共同创立SynGen Inc.，并开始开发可编程系统，提高分离和捕获外周血或胎盘/脐血、骨髓抽吸和白细胞分离纯化干细胞、祖细胞和免疫细胞的速度和效率。2017年7月，SynGen与Thermogenesis Corp(现在是Cesca Therapeutics的子公司)合并，Coelho先生接受了合并后公司的首席技术官职位。 He is now leading the development of CAR-TXpress, an automated method of manufacturing therapeutic doses of CAR T-cells in a functionally closed cell processing system. Mr. Coelho has been a member of the Catalyst Board of Directors since October 2002.

理查德达利

Richard J. Daly于2015年2月加入了董事会催化剂委员会。他目前担任Editchspring Inc.的首席运营官，全球临床生物制药公司开发创新的免疫肿瘤癌症疗法。此前，从2016年起，他是Neuralstem，Inc。的主席兼首席执行官，直到2014年10月，Daly先生担任Astrazeneca美国糖尿病总统，他领导了所有商业和医疗计划和目标，达到22亿美元，3,000亿元，包括成功推出孤儿/稀有紊乱的药物，Myalept，用于脂肪蓄水池。从2011年到2013年，Daly先生担任了一个联合创始人，并为萨格帕伙伴提供了一家提供制药行业的公司，其中包括外包商业服务。From 2008 to 2011, Mr. Daly was employed by Takeda N.A., the North American subsidiary of Takeda Pharmaceuticals, serving first as Vice President, Integration, leading a 6,500-person commercial/R&D merger between TAP Pharmaceuticals and Takeda N.A., then as Executive Vice President of Takeda N.A., with commercial responsibility for all businesses in the Americas. From 2006 to 2008, Mr. Daly served as the Vice President, Commercial Strategy for TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals and Abbott Labs. In 1998, Mr. Daly was a founding member of the leadership team of Takeda Pharmaceuticals N.A., serving initially as the Senior Director of Marketing. Between 1998 and 2006, Mr. Daly took on roles of increasing responsibility culminating in his appointment as Senior Vice President, Marketing (2001-2006). Mr. Daly received his bachelor of science degree in microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.

Donald A. Denkhaus.

Donald A. Denkhaus于2015年2月加入了我们的董事会，目前董事会董事会审计委员会。自2005年以来，丹科斯先生已成为厨房董事长兼首席财务官，LLC，一家为电视业提供语言配音和字幕服务。从1970年到2002年，丹科士先生被许可为一名注册会计师，为全球专业服务组织亚瑟安德森LLP工作，他是二十两年的审计合作伙伴，并举办了众多领导地位，包括掌握of Andersen’s South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen’s offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company currently seeking FDA approval of an antiviral drug, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the Board of Directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly traded specialty pharmaceutical company focused on women’s health and psychiatry. Mr. Denkhaus received an MBA with a major in finance from the University of Maryland and a bachelor’s degree in business administration with a major in accounting from Kent State University.

查尔斯B. O'Keeffe.
领导独立董事

Charles B. O 'Keeffe是弗吉尼亚联邦大学医学院(VCU)药理学、流行病学和社区卫生教授。他在退休后加入VCU，担任Reckitt Benckiser Pharmaceuticals, Inc.的总裁兼首席执行官。O 'Keeffe先生在制药行业和政府方面有着卓越的职业生涯。他曾担任Pharmaceutical Services Inc.的总裁，以及Washington Reference Laboratories的总裁。他曾在白宫为三任总统服务——担任顾问、国际卫生特别助理和药物滥用政策办公室国际事务副主任，并曾为参加世界卫生大会和联合国麻醉药品委员会的美国代表团服务。

大卫·s·蒂尔尼

David S. Tierney，MD目前担任Icon Biosciences Inc.的首席执行官，这是一家私人举行的眼科药物交付公司。此前，Tierney博士曾担任2008年本公司组织的私人专业制药公司Oceana Therapeutics，Inc。的总统兼首席运营官（和董事会成员），直到销售本公司萨利克斯制药有限公司于2011年12月.Tierney博士还担任首席执行官和Valera Pharmaceuticals，Inc。的董事，直到Indevus Pharmaceuticals，Inc。于2007年4月收购。2000年1月至2000年8月, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail’s research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, world¬wide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine. Dr. Tierney also serves on the Board of Directors of Kempharm, Inc.